Uncategorized
Clinical trials accumulate data for novel anti-VEGF
CHICAGO — A new anti-VEGF indicated for use in wet age-related macular degeneration achieved clinically meaningful and durable vision improvement in several studies with reduced dosing, according to a speaker here.Conbercept, a fusion protein produced in a manner similar to Elyea (aflibercept, Regeneron) is approved for use in China, and discussions are underway to bring this drug to the U.S. and other countries, Peter K. Kaiser, MD, told colleagues at the Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.